| (Values in U.S. Thousands) | Apr, 2025 | Apr, 2024 | Apr, 2023 | Apr, 2022 | Apr, 2021 |
| Sales | 0 | 20 | 10 | 10 | 30 |
| Sales Growth | -100.00% | +100.00% | unch | -66.67% | unch |
| Net Income | -8,770 | -6,610 | -6,350 | -4,830 | -2,450 |
| Net Income Growth | -32.68% | -4.09% | -31.47% | -97.14% | unch |
Heartsciences Inc (HSCS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Heart Test Laboratories, Inc. d/b/a HeartSciences is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG's clinical utility. Millions of ECGs are performed every week and the Company's objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences has one of the largest libraries of AI-ECG algorithms and is developing AI-ECG solutions to be made available on either a hardware agnostic cloud-based platform or its proprietary MyoVista' wavECG(TM) device, to help identify cardiovascular disease in any care setting worldwide in a manner to best suit different care providers. HeartSciences' first product candidate for FDA clearance, the MyoVista' wavECG(TM), or the MyoVista(R), is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction.
Fiscal Year End Date: 04/30